Solesence (NASDAQ:SLSN) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

• Solesence (NASDAQ:SLSN) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, reflecting a negative outlook from analysts.
• The company's stock price saw a decline of 2.9% recently, trading at $4.34, with a market capitalization of approximately $304.23 million.
• Insider transactions include COO Kevin Cureton selling 38,807 shares for a total of $147,466.60, marking a significant 16.80% decrease in his ownership.

Solesence (NASDAQ:SLSN - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.

Solesence Trading Down 2.9%

Solesence stock opened at $4.34 on Friday. Solesence has a 1 year low of $1.21 and a 1 year high of $16.56. The firm has a 50 day moving average of $4.15. The stock has a market capitalization of $304.23 million, a P/E ratio of 108.53 and a beta of 0.78.

Insider Transactions at Solesence

In related news, COO Kevin Cureton sold 38,807 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $3.80, for a total value of $147,466.60. Following the completion of the sale, the chief operating officer directly owned 192,212 shares in the company, valued at approximately $730,405.60. The trade was a 16.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Solesence

A hedge fund recently bought a new stake in Solesence stock. Hunter Perkins Capital Management LLC acquired a new position in shares of Solesence, Inc. (NASDAQ:SLSN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 437,872 shares of the company's stock, valued at approximately $1,909,000. Hunter Perkins Capital Management LLC owned 0.62% of Solesence as of its most recent SEC filing. Institutional investors own 70.22% of the company's stock.

About Solesence

Nanophase Technologies Corporation provides engineered materials, formulation development, and commercial manufacturing with an integrated family of technologies in the United States. It offers surface engineered zinc oxide and titanium dioxide for sunscreens and personal care products; fully formulated cosmetics, sun care, and skin care under the Solésence brand name; and advanced materials products, such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and various surface finishing technologies applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.